Last reviewed · How we verify

NCT03268850

Living Kidney Donor Lost Wages Trial

Completed NA Last updated 18 March 2024
What this trial tests

NA trial testing Standard of Care in Kidney Diseases in 453 participants. Completed in 1 May 2023.

Timeline
5 February 2018
Primary endpoint
1 May 2023
1 May 2023

Quick facts

Lead sponsorBeth Israel Deaconess Medical Center
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposeother
Enrollment453
Start date5 February 2018
Primary completion1 May 2023
Estimated completion1 May 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Beth Israel Deaconess Medical Center

Who can join

18 and older, any sex, with Kidney Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to evaluate the effectiveness of offering reimbursement for living donor lost wages on the rate of live donor kidney transplantation.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

  1. The Living Donor Lost Wages Trial: Study Rationale and Protocol.
    Rodrigue JR, Fleishman A, Carroll M, Evenson AR, et al · · 2018 · cited 8× · PMID 29805957 · DOI 10.1007/s40472-018-0182-0

Verify or expand the search:

Other trials of Standard of Care

Trials testing the same drug.

Other recruiting trials for Kidney Diseases

Currently open trials in the same condition.

Other Beth Israel Deaconess Medical Center trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03268850.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing